Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2010 / Cilt: 36 - Sayı: 2

Skeletal system complications of the prostate, bladder and kidney tumors and biphosphonate treatment

Prostat, mesane ve böbrek tümörlerinin iskelet sistemi ve bifosfonat tedavisi

Pages
112–118
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Currently, biphosphonates are recommended in various treatment guidelines to treat bone metastasis in a variety of cancers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Genitourinary system tumors are the most common tumors with bone metastases.
📊
Key Findings & Data:The health-related quality of life is affected significantly in these patients, due to the skeletal-related events.
💡
Conclusion & Impact:Currently, biphosphonates are recommended in various treatment guidelines to treat bone metastasis in a variety of cancers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Genitourinary system tumors are the most common tumors with bone metastases. Bone metastases are observed in advanced prostate, bladder and kidney cancers. The health-related quality of life is affected significantly in these patients, due to the skeletal-related events. Men who receive androgen deprivation therapy for prostate cancer are under more risk for osteoporosis. Pathological bone fractures, compression of the spinal cord, requirement of radiotherapy or surgical intervention to bone, and hypercalcemia due to cancer are the skeletal-related events that develop in these patients. In addition to the corrections in living conditions, exercise, reducing smoking and alcohol consumption, and calcium and vitamin D supplements; the biphosphonates have become an indispensible part of the treatment to prevent these events with their benefits demonstrated in various studies in the recent years. Especially zoledronic acid, which is well tolerated with intravenous application, is used both in the treatment of bone metastases and in prevention of skeletal-related events. Currently, biphosphonates are recommended in various treatment guidelines to treat bone metastasis in a variety of cancers.

Özet

Genitoüriner sistem tümörleri kemiğe en sık metastaz yapan tümörlerdendir. İlerlemiş prostat, mesane ve böbrek kanserlerinde kemik metastazları görülür. Bu hastalarda sağlıkla ilgili yaşam kalitesi, kemikle ilişkili gelişen çeşitli olaylar nedeniyle önemli derecede etkilenir. Özellikle de androjen baskılama tedavisi alan prostat kanserli erkekler, osteoporoz için daha fazla risk altındadır. Patolojik kemik kırıkları, spinal kord basısı, kemiğe radyoterapi uygulanması veya cerrahi müdahale yapılması gereği ve maligniteye bağlı hiperkalsemi, bu hastalarda kansere bağlı gelişen kemikle ilgili olaylardır. Bu olayların önlenmesi için, yaşam koşullarının düzeltilmesi, egzersiz yapılması, sigara ve alkolün azaltılması, kalsiyum ve D vitamini desteğinin yanında, son yıllarda çeşitli çalışmalarla faydası gösterilen bifosfonatlar artık tedavinin vazgeçilmez bir parçası olmaya başlamıştır. Özellikle intravenöz uygulama ile iyi tolere edilebilen zoledronik asit, hem kemik metastazlarının tedavisine hem de kemikle ilgili olayları önleme amacıyla kullanıma girmektedir. Günümüzde çeşitli kılavuzlarda bifosfonatların farklı kanserlerin kemik metastazında tedavi amacıyla kullanılması önerilmektedir.

🔖

Cite This Article

ATEŞ, F., BAYKAL, K. V. (2010). Skeletal system complications of the prostate, bladder and kidney tumors and biphosphonate treatment. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 36 - Sayı: 2, 112–118. https://ajindex.com/articles/328682

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001
  2. PMID: 11417967 2. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997
  3. PMID: 8996327 3. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003
  4. PMID: 12941198 4. Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 2003
  5. PMID: 12604128 5. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988
  6. PMID: 3334948 6. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic signifi cance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999
  7. PMID: 10071289 7. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005
  8. PMID: 15983391 8. Gill RK, Turner RT, Wronski TJ, Bell NH. Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor in rat bone, and reduction is prevented by testosterone. Endocrinology 1998
  9. PMID: 9449623 9. Gainor BJ, Fracture healing in metastatic bone disease. Clin Orthop Relat Res 1983
  10. PMID: 6883864 10. Jacofsky DJ, Haidukewych GJ. Management of pathologic fractures of the proximal femur: state of the art. J Orthop Trauma 2004
  11. PMID: 15289695 11. Cree M, Soskolne CL, Belseck E, Hornig J, McElhaney JE, Brant R, et al. Mortality and institutionalization following hip fracture. J Am Geriatr Soc 2000
  12. PMID: 10733054 12. Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999
  13. 54(Suppl 6A):8-14. PMID: 10606278 13. Coleman RE. Skeletal complications of malignancy. Cancer 1997 15
  14. 80(Suppl 8):1588-94. PMID: 9362426 14. Abrahm JL. Assessment and treatment of patients with malignant spinal cord compression. J Support Oncol 2004
  15. PMID: 15524067 15. Poor G, Atkinson EJ, Lewallen DG, O’Fallon WM, Melton 3rd LJ. Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporos Int 1995
  16. PMID: 8695962 16. Oefelein MG,